GlassScriptPhysician profile
Isra M Amer
NPI 1356469142
$4,987.40
in general payments reported to CMS, 2019-2025
38 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $392 · 2021: $815 · 2022: $717 · 2023: $919 · 2024: $722 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,948.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $724.24 | 2020-2025 | Ozempic, Rybelsus |
| Amgen INC. | $548.70 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $487.71 | 2021-2025 | Qulipta |
| Pfizer INC. | $378.69 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $360.17 | 2019-2025 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $317.03 | 2022-2025 | |
| Lilly USA, LLC | $246.23 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $199.41 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $185.91 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.62 | 2021-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $146.35 | 2020-2025 | Veozah |
| Merck Sharp & Dohme LLC | $126.94 | 2020-2025 | Belsomra, Capvaxive, Steglatro |
| Exact Sciences Corporation | $114.68 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.87 | 2021-2024 | |
| Inspire Medical Systems, INC. | $98.32 | 2024-2025 | Inspire |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isra Amer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.